| Company/Division name | Wilmington PharmaTech |
| Parent company | Curewell Capital |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2026 |
| Year reshoring implemented or to be implemented: | 2027 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Wilmington |
| State(s) reshored to: | DE |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals, Small-Molecule APIs |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
